search
Back to results

Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children

Primary Purpose

Diarrhea

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Racecadotril
DiaResQ Children's Powder for Suspension
Sponsored by
Shaheed Zulfiqar Ali Bhutto Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diarrhea

Eligibility Criteria

1 Year - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration

Exclusion Criteria:

  • Children requiring emergency resuscitation.
  • Children having diarrhea of more than 15 days duration..
  • Children with other comorbid conditions like heart, kidney and liver failure.
  • Children with fructose intolerance, glucose malabsorption syndrome and saccharase isomaltase deficiency.
  • Children allergic to egg or any of the contents.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Group A

    Group B

    Arm Description

    Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration

    Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration

    Outcomes

    Primary Outcome Measures

    frequency of diarrheal episodes
    reduction in frequency of diarrheal episodes after administration of drug

    Secondary Outcome Measures

    Full Information

    First Posted
    May 9, 2021
    Last Updated
    August 22, 2021
    Sponsor
    Shaheed Zulfiqar Ali Bhutto Medical University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04885049
    Brief Title
    Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children
    Official Title
    A Randomized Controlled Trial Comparing the Efficacy of Anti Secretory and Oral Immunoglobulins Reducing the Episodes of Diarrhea in Children
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    September 1, 2021 (Anticipated)
    Primary Completion Date
    February 1, 2022 (Anticipated)
    Study Completion Date
    February 1, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Shaheed Zulfiqar Ali Bhutto Medical University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Children 1-12 years presenting/admitted with acute diarrhea will be enrolled in the study after taking informed consent from the parents. Patients will be randomly allocated to two equal groups. Group A (GA) will receive anti secretory 1.5mg/kg/dose, three doses in 24 hours along with oral rehydration, while Group B (GB) will receive a single dose of bovine immunoglobulins. Response to treatment will be assessed by recording the frequency of loose stools after 72 hrs. Data will be collected through a structured proforma.
    Detailed Description
    It is a randomized clinical trial that will be conducted at Children Hospital PIMS, Islamabad over the period of 6 months. Sample size is calculated using World Health Organization (WHO) calculator, keeping confidence level 95%, level of significance 5%, power of the test 80%,anticipated population proportion 1: 84%, anticipated population proportion 2: 93%, which turn out to be 30.Consecutive non probability sampling technique will be used. Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration will be enrolled in the study after taking informed consent from the parents. Children requiring emergency resuscitation, having chronic diarrhea i-e more than 15 days duration, having other comorbid conditions like heart, kidney and liver failure, having metabolic disorder and who are allergic to egg or any of the contents will be excluded from the study. Child's name, age, sex will be recorded by the on duty doctor. Patients will be randomly allocated to two equal groups. Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours along with oral rehydration, while Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration. Response to treatment will be assessed by recording the reduction in frequency of diarrheal episodes after administration of drug and duration in which the diarrheal episodes were reduced. Data will be collected through a structured proforma. All data will be analyzed using latest SPSS version. Quantitative variables such as age, time will be presented as means and standard deviations. Qualitative variables such as age groups, sex, recurrence of seizures and efficacy will be measured as frequency and percentages. Effect modifiers like age, gender will be controlled by stratification. Post stratification chi-square test will be applied keeping p value ≤0.05 as significant.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diarrhea

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Group A
    Arm Type
    Experimental
    Arm Description
    Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
    Arm Title
    Group B
    Arm Type
    Experimental
    Arm Description
    Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
    Intervention Type
    Drug
    Intervention Name(s)
    Racecadotril
    Intervention Description
    Anti secretary
    Intervention Type
    Drug
    Intervention Name(s)
    DiaResQ Children's Powder for Suspension
    Intervention Description
    oral immunoglobulins
    Primary Outcome Measure Information:
    Title
    frequency of diarrheal episodes
    Description
    reduction in frequency of diarrheal episodes after administration of drug
    Time Frame
    24 to 72 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Year
    Maximum Age & Unit of Time
    12 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration Exclusion Criteria: Children requiring emergency resuscitation. Children having diarrhea of more than 15 days duration.. Children with other comorbid conditions like heart, kidney and liver failure. Children with fructose intolerance, glucose malabsorption syndrome and saccharase isomaltase deficiency. Children allergic to egg or any of the contents.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Nighat Haider, FCPS
    Phone
    +92519107695
    Email
    nighathaider@hotmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nighat Haider, FCPS
    Organizational Affiliation
    Shaheed Zulfiqar Ali Bhutto Medical University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    If somebody wants the IPD they can email the principal investigator and it will be provided after the publication
    IPD Sharing Time Frame
    6 months after publication of data.
    IPD Sharing Access Criteria
    If somebody wants the IPD they can email the principal investigator and it will be provided

    Learn more about this trial

    Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children

    We'll reach out to this number within 24 hrs